In 2017 agroup of scientists including Irminger-Finger conducted...

In 2017 agroup of scientists including Irminger-Finger conducted study to determine the presence of anti-BARD1 antibodies in cancer patients. They tested sera from 93 patients with lung cancers and 94 controls with 33 peptides and seven BARD1 fragments in ELISA assays. For the majority of antigens (29 out of 40) - p-value is lower than 0.05 (means sstatistically significant), and for 15 peptides lower than 0.01. Two methods were used. The first method resulted in a sensitivity of 0.80 and specificity of 0.78. The second method was 0.9/0.61 respectively (Pilyugin et al., 2017). Three years since this study was published. So could be more promising results.